Complete primary sequences of two lambda immunoglobulin light chains in myelomas with nonamyloid (Randall-type) light chain deposition disease.

We herein report on the first two primary sequences (BOU and RAC) of monoclonal light chains of the lambda type responsible for nonamyloid lambda light chain deposition disease. Both patients were affected with severe forms of myeloma complicated with renal failure. The pathological presentation typically featured Congo red-negative deposits along tubular basement membranes but differed somewhat from the typical "Randall-type" kappa light chain deposition disease: they lacked the prominent glomerulosclerosis pattern often featuring nonamyloid kappa deposits and were associated with cylinders or myeloma casts. Both protein sequences were deduced from those of the corresponding complementary DNAs in the bone marrow plasma cells. For each chain, products of three independent amplifications by polymerase chain reaction were sequenced and found to be identical. BOU and RAC lambda mRNAs had a normal overall structure consisting of Vlambda2 segments rearranged to Jlambda2Clambda2 but displayed a number of unusual features within their primary sequences. These substitutions are likely responsible for changes in light chain conformation that promote their aggregation and deposition along renal tubule basement membranes.

• Publication year

  1998

• Venue

  American Journal of Pathology

• Publication date

  1998-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0002-9440(10)65573-3PMID 9665493PMCID PMC1852939
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Light chain deposition disease of the kidney. Morphological aspects in 24 patients

  2004cited by this paper
• One-megabase sequence analysis of the human immunoglobulin lambda gene locus.

  1997cited by this paper
• Specificity of abnormal assembly in immunoglobulin light chain deposition disease and amyloidosis.

  1996cited by this paper
• Light chain cardiomyopathy. Structural analysis of the light chain tissue deposits.

  1996cited by this paper
• Structural peculiarities of a truncated V kappa III immunoglobulin light chain in myeloma with light chain deposition disease.

  1996cited by this paper
• Structural peculiarities of a truncated VκIII immunoglobulin light chain in myeloma with light chain deposition disease

  1996cited by this paper
• Structural and functional characterization of three human immunoglobulin kappa light chains with different pathological implications.

  1996cited by this paper
• Role of light chain variable region in myeloma with light chain deposition disease: evidence from an experimental model.

  1995cited by this paper
• Preferential expression of human λ-light-chain variable-region subgroups in multiple myeloma, AL amyloidosis, and Waldenström's macroglobulinemia

  1995cited by this paper
• Structure and properties of human immunoglobulin light-chain dimers.

  1995cited by this paper
• Tertiary structure of an amyloid immunoglobulin light chain protein: a proposed model for amyloid fibril formation.

  1995cited by this paper
• A molecular model for self-assembly of amyloid fibrils: immunoglobulin light chains.

  1995cited by this paper
• A role for destabilizing amino acid replacements in light-chain amyloidosis.

  1994cited by this paper
• Recombinant immunoglobulin variable domains generated from synthetic genes provide a system for in vitro characterization of light‐chain amyloid proteins

  1994cited by this paper
• Overrepresentation of the V kappa IV subgroup in light chain deposition disease.

  1994cited by this paper
• Monoclonal immunoglobulin deposition disease: a review of immunoglobulin chain alterations.

  1994cited by this paper
• Preferential expression of human lambda-light-chain variable-region subgroups in multiple myeloma, AL amyloidosis, and Waldenström's macroglobulinemia.

  1994cited by this paper
• Overrepresentation of the VϰIV subgroup in light chain deposition disease

  1994cited by this paper
• Cloning and sequencing of human immunoglobulin λ. gene segments

  1993cited by this paper
• Primary structure of a variable region of the V kappa I subgroup (ISE) in light chain deposition disease.

  1993cited by this paper
• Primary structure of a variable region of the VI subgroup (ISE) in light chain deposition disease

  1993cited by this paper
• Primary structure of a monoclonal kappa chain in myeloma with light chain deposition disease.

  1992cited by this paper
• Structurally abnormal immunoglobulins in human immunoproliferative disorders.

  1992cited by this paper
• Structure and expression of the mb‐1 transcript in human lymphoid cells

  1992cited by this paper
• Primary structure of a monoclonal κ chain in myeloma with light chain deposition disease

  1992cited by this paper
• Complementary DNA sequence of human amyloidogenic immunoglobulin light-chain precursors.

  1992cited by this paper
• Sequences of proteins of immunological interest

  1991cited by this paper
• Structure of a monoclonal kappa chain of the V kappa IV subgroup in the kidney and plasma cells in light chain deposition disease.

  1991cited by this paper
• Amino acid sequence of k Sci, the Bence Jones protein isolated from a patient with light chain deposition disease.

  1991cited by this paper
• Structure and expression of the human immunoglobulin lambda genes

  1990cited by this paper
• Serologically defined V region subgroups of human lambda light chains.

  1987cited by this paper
• Canonical structures for the hypervariable regions of immunoglobulins.

  1987influential reference
• Characterization of renal amyloid derived from the variable region of the lambda light chain subgroup II.

  1986cited by this paper
• The amino acid sequence of a carbohydrate-containing immunoglobulin-light-chain-type amyloid-fibril protein.

  1985cited by this paper
• Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia.

  1985cited by this paper
• Enzymatic amplification of ?-globin genomic sequences and restriction site analysis for diagnosis of

  1985cited by this paper
• Light-chain deposition disease: its relation with AL-type amyloidosis.

  1984cited by this paper
• The complete amino acid sequence of a prototype immunoglobulin-lambda light-chain-type amyloid-fibril protein AR.

  1981cited by this paper
• Synthesis of abnormal heavy and light chains in multiple myeloma with visceral deposition of monoclonal immunoglobulin.

  1980cited by this paper
• Synthesis of abnormal immunoglobulins in lymphoplasmacytic disorders with visceral light chain deposition.

  1980cited by this paper
• DNA sequencing with chain-terminating inhibitors.

  1977cited by this paper

• Role of the mechanisms for antibody repertoire diversification in monoclonal light chain deposition disorders: when a friend becomes foe

  2023cites this paper
• Understanding Mesangial Pathobiology in AL-Amyloidosis and Monoclonal Ig Light Chain Deposition Disease

  2020cites this paper
• Light Chain Deposition Disease

  2019cites this paper
• Healing the damaged mesangium in nodular glomerulosclerosis using mesenchymal stem cells (MSCs): Expectations and challenges

  2016cites this paper
• Animal Models of Light Chain Deposition Disease Provide a Better Understanding of Nodular Glomerulosclerosis

  2016cites this paper
• Impact de la production des immunoglobulines tronquées sur le développement lymphocytaire B normal et tumoral

  2016cites this paper
• [Randall-type monoclonal immunoglobulin deposition disease: From diagnosis to treatment].

  2016cites this paper
• [Randall-type monoclonal immunoglobulin deposition disease: From diagnosis to treatment].

  2016cites this paper
• Monoclonal Immunoglobulin Deposition Disease

  2014cites this paper
• Role of translational research advancing the understanding of the pathogenesis of light chain‐mediated glomerulopathies

  2007cites this paper
• Light Chain Deposition Disease

  2007cites this paper
• Disease of the Month Multiple Myeloma

  2006cites this paper
• Where disease pathogenesis meets protein formulation: renal deposition of immunoglobulin aggregates.

  2006cites this paper
• ROLE OF THE MONOCLONAL κ CHAIN V DOMAIN AND REVERSIBILITY OF RENAL DAMAGE IN A TRANSGENIC MODEL OF ACQUIRED FANCONI’S SYNDROME

  2006cites this paper
• Role of the monoclonal kappa chain V domain and reversibility of renal damage in a transgenic model of acquired Fanconi syndrome.

  2006cites this paper
• Immunologic basis for the rare occurrence of true nonsecretory plasma cell dyscrasias

  2004cites this paper
• A monoclonal V kappa l light chain responsible for incomplete proximal tubulopathy.

  2003cites this paper
• A monoclonal Vκl light chain responsible for incomplete proximal trubulopathy

  2003cites this paper
• Régulation concertée de l'expression des chaînes d'immunoglobulines et conséquences de ses anomalies en pathologie

  2003cites this paper
• Tumoral non‐amyloidotic monoclonal immunoglobulin light chain deposits (‘aggregoma’): presenting feature of B‐cell dyscrasia in three cases with immunohistochemical and biochemical analyses

  2002cites this paper
• The contributions of electron microscopy to the understanding and diagnosis of plasma cell dyscrasia-related renal lesions

  2001cites this paper
• Physiopathologie des amyloses

  2000cites this paper
• Renal manifestations of plasma cell dyscrasias: an appraisal from the patients' bedside to the research laboratory.

  2000cites this paper
• Amyloidosis physiopathology.

  2000cites this paper
• Nonamyloidotic monoclonal immunoglobulin deposition disease. Light-chain, heavy-chain, and light- and heavy-chain deposition diseases.

  1999cites this paper
• Mutational analysis in murine models for myeloma-associated Fanconi's syndrome or cast myeloma nephropathy.

  1999cites this paper
• Somatic mutations of the L12a gene in V-kappa(1) light chain deposition disease: potential effects on aberrant protein conformation and deposition.

  1999cites this paper
• Glomerulopathic light chain-mesangial cell interactions modulate in vitro extracellular matrix remodeling and reproduce mesangiopathic findings documented in vivo.

  1999cites this paper
• Scholars Journal of Medical Case Reports

  year unknowninfluential citation